

STARTUP DEMO DAY

Innovative Startups in 5P Digital Medicine

Madeira, Portugal | September 17, 2026

Investor E-Book



**Funded by
the European Union**

About InnoMedCatalyst Project

The InnoMedCatalyst is an I3 project funded by the European Union, designed to enhance the regional innovation capacity of precision and personalized medicine ecosystems across Europe. Through actions such as the **InnoMedCatalyst Accelerator Programme**, startups, spinoffs, early-stage SMEs and healthcare providers strengthen their ability to develop, test and refine digital health solutions as viable business cases, paving the way for investment-ready interregional projects by 2026. With 13 consortium partners representing **10 European regions -North-East Romania, Małopolska, Emilia-Romagna, Flanders, Catalonia, Castilla y León, Attica, Sofia, Norte and Madeira**, the project is catalysing the innovation potential of the **MEDIC NEST Digital Precision Medicine** ecosystem and beyond.

As part of its core objectives, InnoMedCatalyst is further developing **10 regional roadmaps**, alongside **one Interregional Roadmap for 5P Digital Medicine**, and a **Portfolio of Interregional Investment Projects**, shaping a cohesive and forward-looking European White Paper for the adoption and scale-up of digital healthcare solutions.

This project has received funding from the European Union under Grant Agreement No. 101180513.



**Funded by
the European Union**



Company Description

3-Fi Ltd. (Varna/Sofia, Bulgaria) develops 3-Fi Medical: a cloud-first Software-as-a-Medical-Device (SaMD) platform that reduces missed or delayed neuro-cardiac deterioration in acute care.

Building on 3-Fi's track record in embedded and real-time signal-processing engineering, we automate electroencephalography (EEG) event detection and clinician-grade annotation (e.g. non-convulsive seizures/status epilepticus, burst suppression, low-voltage activity, artefacts) and push real-time, centralized alerts to the right team with full auditability.

The platform is designed to integrate with existing bedside monitors and electronic health records via open, modular connectors - minimizing adoption cost and avoiding vendor lock-in. Continuous monitoring also generates structured, privacy-preserving datasets that enable trustworthy model improvement and clinical research.

Organization name: 3-Fi Ltd.

Country: Bulgaria

Type of company: Startup

Year of Foundation: 2021

TRL Level: 4

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Equity

Investment Required: €950K

Product / Solution

3-Fi Medical is a cloud-first, B2B Software-as-a-Medical-Device platform for centralized neuro-cardiac monitoring and alerting in the intensive care unit (ICU). The current focus is EEG: the system ingests continuous electroencephalography streams from existing monitors, performs automated clinician-grade annotation and event detection, and produces alarms where escalation is required in real time with a full audit trail (e.g. non-convulsive seizures/status epilepticus, burst suppression, low-voltage activity, artefacts). Near-term expansion adds electrocardiogram (ECG) fusion for higher fidelity detection and risk scoring.

Beyond clinical workflow support, we provide a medical-AI development environment for research and commercial use: data anonymisation and structuring, dataset curation and quality assurance, visualisation, and a node-based execution backend that lets vetted users run or develop algorithms (Python/R) without vendor lock-in. The backend is modular and flexible enough to empower future developments and goals in support of Europe's personalised medicine initiatives.

Business model: subscription SaaS (per bed / per user) plus paid integrations and optional data/algorithm marketplace services. Dedicated multimodal monitoring hardware is included in the roadmap at a later stage.

CONTACT

Trifon Tsekov, Founder & CEO

E-mail: trifon.tsekov@3-fi.com

Website: <https://3-fi.com/>

ABCURED

Connecting the genetic dots with AI

Company Description

ABCureD PC is a deep-tech university spin-off developing next-generation diagnostics that combine molecular biology and artificial intelligence to enable earlier detection and prevention of complex diseases. Our validated discovery pipeline translates advanced multi-omics research into scalable clinical tools that support precision medicine and data-driven healthcare.

Our flagship technology, LPancreas, is a versatile next-generation diagnostic platform assessing pancreatic decline—the fundamental pathological driver of diabetes that is currently not assessed by standard diagnostics. The platform integrates liquid biopsy, epigenetic biomarkers and machine learning algorithms to generate a clinically actionable score reflecting pancreatic health. By identifying disease processes before irreversible damage occurs, LPancreas enables earlier intervention, improved risk stratification and personalized disease management. Its minimally invasive approach allows broad deployment through diagnostic laboratories and potentially point-of-care settings, addressing the urgent need in a rapidly growing global diabetes population.

ABCureD combines strong academic expertise, entrepreneurial experience and international collaborations to advance toward clinical validation, regulatory approval and commercialization. The company's long-term vision is to establish a new category of AI-driven precision diagnostics, transforming how chronic diseases are detected, monitored and prevention.

Organization name:

ABCureD Private Company

Country: Greece

Type of company: Startup/Spinoff

Year of Foundation: 2022

TRL Level: 5

Estimated 5-Year Revenue Post-Launch: €500K-€1M

Funding Instrument: Equity

Investment Required: €1M

Product / Solution

ABCureD is developing LPancreas, a next-generation diagnostic platform designed to detect and quantify pancreatic β -cell decline—the underlying biological driver of diabetes that is not currently measured by standard diagnostics. LPancreas is a minimally invasive blood-test using standard PCR technology linked to a machine learning algorithm used to generate a score reflecting pancreatic health and disease progression.

Current diabetes diagnostics rely mainly on glucose-based measurements (e.g., HbA1c or fasting glucose), which identify the disease result (high glucose) rather than the disease early cause (pancreatic decline). LPancreas addresses this critical gap by enabling detection of pancreatic dysfunction, allowing timely preventive interventions, improved risk stratification and more personalized treatment decisions. Its blood-based format allows easy integration into existing laboratory workflows and potential adaptation to point-of-care testing. It can also be a valuable tool for pharma drug R&D, to capture directly ongoing pancreatic cell loss for candidate selection, response and toxicity monitoring.

ABCureD's primary business model is B2B, targeting diagnostic laboratories, healthcare providers and diagnostic industry partners that will incorporate LPancreas into routine testing and preventive screening programs. In the longer term, the solution may also enable B2C access through healthcare providers and digital health platforms, empowering individuals at risk of diabetes to monitor pancreatic health and take preventive action earlier.

CONTACT

Katerina Alexiou Chatzaki, Founder & CEO

E-mail: achatzak@med.duth.gr

Website: <https://abcured.com/>



Company Description

AimaLabs is an AI-driven SaaS company developing a fully hardware-independent platform for automated peripheral blood smear (PBS) analysis. Founded by Dr. Vasiliki Vlacha, PhD Christos Maniatis and Daniel Tikhomirov AimaLabs unites deep clinical expertise with cutting-edge AI engineering.

The platform addresses a critical global diagnostic gap: 84% of 5+ billion annual Complete Blood Counts lack necessary follow-up smear review, impacting 1.5 billion patients. Existing digital morphology solutions require €100,000+ in capital expenditure, excluding the vast majority of European laboratories. AimaLabs eliminates this barrier entirely — working with any standard microscope and camera to deliver WBC differentials, ICSH-aligned RBC morphology grading, platelet estimation, and high-risk cell flagging in under 2 minutes, with accuracy up to 97%.

The zero-CapEx SaaS model (€10K setup + €15K annual license + €2.00/CBC) frees 5.7 FTE per facility and delivers measurable cost savings from day one. Our vision is to make specialist-level haematology diagnostics accessible to every laboratory in the world — regardless of geography, resources, or infrastructure. Beginning with CE submission within 18 months and commercial launch in Greece and EU5 markets in 2029, AimaLabs is building toward a global standard for democratised, AI-powered diagnostics.

Organization name: AimaLabs

Country: Greece

Type of company: Startup

Year of Foundation: 2024

TRL Level: 4

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Equity

Investment Required: €750K

Product / Solution

AimaLabs is a software-only, AI-powered SaaS platform for automated peripheral blood smear (PBS) analysis — hardware-independent and compatible with any standard laboratory microscope and camera.

A laboratory professional captures or uploads a smear image; the AI processes it in under 2 minutes, delivering WBC differential, ICSH-aligned RBC morphology grading, platelet estimation, and high-risk cell flagging (blasts, schistocytes, sickle cells) with accuracy up to 97%. A qualified professional then validates the result, reducing review time by up to 80%. Unlike competitors (CellaVision, Scpio, Sysmex DI-60), AimaLabs requires zero capital expenditure — no proprietary hardware — making specialist-level morphology accessible to the 79–100% of laboratories currently excluded by high-CapEx solutions.

AimaLabs is a B2B solution. Target customers span public and private hospital haematology departments, independent and reference laboratories, consolidated diagnostic networks, and resource-constrained facilities in emerging markets. Revenue is generated through a €10,000 one-time implementation fee, €15,000 annual license, and €2.00 per-CBC usage fee. Cloud-based and scalable, the platform integrates seamlessly into existing laboratory information systems, enabling rapid deployment across diverse multi-site environments globally.

CONTACT

Vasiliki Vlacha, CEO

E-mail: vasovlaha@gmail.com

Website: <https://aimalabs.net/>



Company Description

Ce.B.Tec. P.C. is a biotechnology company and spin-off of the Agricultural University of Athens specializing in advanced diagnostics and point-of-care technologies. The company develops bioelectric biosensor solutions based on Molecular Identification through Membrane Engineering, enabling fast, sensitive, and cost-effective diagnostic tests.

With over 25 years of research expertise, Ce.B.Tec. focuses on applications in healthcare, agri-food, environmental monitoring, and biotechnology. Its technologies support the rapid detection of pathogens and biomarkers, including respiratory viruses such as SARS-CoV-2, through flexible and portable diagnostic platforms.

The company also provides consulting, contracted research and development, and analytical services, while actively participating in national and European research projects. Recognized for its innovation, Ce.B.Tec. has received awards including the Johnson & Johnson Idea Incubator Award for its SARS-CoV-2 biosensor assay and a distinction at the National Defense Innovation Challenge for a portable anthrax detection test.

Through continuous research and innovation, Ce.B.Tec. aims to advance next-generation diagnostic technologies and expand its presence in the global market for portable diagnostic devices.

Organization name: Ce.B.Tec. P.C.

Country: Greece

Type of company: Spinoff

Year of Foundation: 2023

TRL Level: 5

Estimated 5-Year Revenue Post-Launch: €500K-€1M

Funding Instrument: Equity

Investment Required: €1.8M

Product / Solution

The product is an innovative bioelectric biosensor for rapid, multiplex detection of respiratory pathogens and their antibodies at the point of care (POC). The system combines Bioelectric Recognition Assay (BERA) and Molecular Identification through Membrane Engineering (MIME) technologies to provide fast, sensitive, and cost-effective diagnostics. Engineered cells displaying specific receptors are immobilized on disposable screen-printed electrodes. When a sample interacts with these cells, target molecules bind to the receptors, causing measurable changes in cell membrane potential that generate a bioelectrical signal.

The signal is detected by a portable device connected to a mobile application, enabling real-time measurement, wireless data transmission, and instant digital reporting of results within approximately three minutes, without sample pre-treatment. The system allows either simultaneous testing of multiple samples or multiplex detection of different pathogens in a single sample. The technology builds on patented biosensor principles and cell-engineering methods, supporting flexible detection of emerging respiratory pathogens. Its performance combines the speed and portability of antigen tests with the sensitivity and specificity of molecular diagnostics.

Currently at Technology Readiness Level (TRL) 5, the project aims to deliver a fully commercial prototype (TRL 8), establish a scalable manufacturing process, and obtain regulatory certifications.

CONTACT

Sofia Mavrikou, Co-Founder & CEO

E-mail: smavrikou@cebttec.eu; info@cebttec.eu

Website: <https://cebttec.eu/>



Company Description

CLAB Neuro Sound Solutions revolutionizes neurotrauma rehabilitation with rigorous sound medicine science. We are a deep tech company developing proprietary sound-based therapies and digital health solutions for neurologic rehabilitation, specifically targeting underserved medical needs and populations.

CLAB combines clinical research with novel software based solutions to deliver non-invasive, scalable sound therapies for brain recovery across the full spectrum of neurotrauma, including currently untreated conditions such as Disorders of Consciousness. CLAB's comprehensive 360° paradigm supports patients left behind by conventional therapies, powered by a 3-pillar framework, integrating clinically validated treatment protocols, software development & education programs. Our methodology combines traditional sound medicine practices with innovations in neurotherapeutics & state of the art sound technology.

Our precision medicine approach tailors personalised sound-based interventions to individual neurological profiles, uniquely targeting cognitive, physical, & emotional rehabilitation. Underpinning our clinical work is a novel sound-based analysis framework - a breakthrough foundation for developing proprietary, patentable, non-invasive therapeutic and predictive applications, with wide cross-sector applications. We are composed of an interdisciplinary team & scientific advisory board with a proven track record in sound health, neurorehabilitation, and technology.

Organization name:
CLAB Neuro Sound Solutions

Country: Greece

Type of company: Startup

Year of Foundation: 2025

TRL Level: 4

5-Year Revenue Projection after Market Launch: >€8M

Funding Instrument: Equity / Grant

Investment Required: €1M

Product / Solution

As health systems seek scalable data-driven tools and next generation precision medicine functional paradigms, CLAB offers a comprehensive, non-invasive & science-backed solution for neurologic rehabilitation providers worldwide. Sound and music are the only stimuli to simultaneously activate multiple neural tracts - validated across clinical studies, health economics and institutional analyses as an optimal neurorehabilitation paradigm.

CLAB's solution combines proprietary sound technologies with novel therapeutic protocols to ensure rapid rehabilitation. All protocols are co-developed in collaboration with neurologists, sound researchers and patient focus groups, and subject to rigorous clinical validation for safety and efficacy assurance. Built on a multi-layered therapeutic approach and deep sound expertise, our technology harnesses sound's rhythmic, spectral and topographic properties to simultaneously drive neuroplasticity, emotional and physiologic regulation.

Our breakthrough methodologies have demonstrated statistically significant results after short exposure, which medications and standard rehabilitation could not achieve in months to years with these specific patients. We ensure our developments are modular and portable while delivering an immersive and engaging experience that drives patient adherence and motivation - a critical gap in standard rehabilitation. CLAB's methodology incorporates machine learning, computer vision and advanced audio analysis and projection frameworks to create personalised data-driven solutions.

Our model is designed for direct integration within established neurorehabilitation centres, utilising existing clinical infrastructure to ensure patient accessibility, operational efficiency and seamless integration. CLAB operates a dual B2B and B2C model, with a Value Base Care (VBC) focus. As adoption matures and robust clinical data accumulates, direct B2C and reimbursement pathways will unlock CLAB's full market potential.

CONTACT

Rona Geffen, Founder & CEO

E-mail: info@ronageffen.com

Website: NA

DrūgBin

Reduce. Save. Protect.

Company Description

DrugBin is a Romanian healthtech startup developing an innovative solution for the safe and automated collection of expired or unused medications generated by the general population. In Romania, this process is managed primarily by public and private hospitals, while the solution is also highly adaptable for pharmacies and other healthcare facilities across Europe.

DrugBin combines smart hardware with artificial intelligence to automatically scan, identify, and sort medications deposited by users or healthcare personnel. The system securely stores pharmaceutical waste and generates digital records and reports that improve traceability, transparency, and regulatory compliance.

Improper disposal of medicines represents a major environmental and public health challenge. Every year, significant quantities of pharmaceutical waste contribute to environmental contamination and antimicrobial resistance, while manual handling exposes healthcare staff to hazardous or cytotoxic substances.

DrugBin addresses these challenges through a fully automated, secure, and accessible medication collection system designed to operate 24/7 within hospitals and healthcare institutions. The company is currently at the proof-of-concept stage, with the core technology already validated. The next phase focuses on developing the final MVP, initiating the certification process, and launching pilot deployments in hospital environments.

Organization name: DrugBin

Country: Romania

Type of company: Startup

Year of Foundation: 2023

TRL Level: 4

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Grant

Investment Required: NA

Product / Solution

DrugBin is a smart hardware and software solution designed to automate the safe collection and management of expired or unused medications returned by the population. The platform integrates artificial intelligence, computer vision, and secure storage technologies to automatically scan, identify, and sort pharmaceutical products deposited by users.

The solution can classify medications by category — including antibiotics, cytotoxic drugs, and general pharmaceuticals — and securely store them to prevent unauthorized access, misuse, or contamination. DrugBin also generates digital records and detailed reporting on collected pharmaceutical waste, improving traceability, transparency, and regulatory compliance for healthcare institutions.

The system is primarily intended for public and private hospitals in Romania, where medication take-back activities from the population are currently managed, while also being suitable for pharmacies, clinics, and other healthcare facilities across Europe.

By enabling safe, convenient, and automated medication disposal, DrugBin contributes to reducing pharmaceutical pollution, preventing improper drug use, and protecting healthcare professionals from exposure to hazardous waste. The product is currently at the proof-of-concept stage (TRL 4–5), with the next development phase focused on building the MVP and preparing pilot implementation in a hospital environment.

CONTACT

Laura Gavriloaia, CEO

E-mail: drugbin.solution@gmail.com

Website: <https://www.drugbin.ro/>



Company Description

EASYMEDAI MEDICAL DATA S.L. (EasyMed) is a deep tech startup founded in 2025, headquartered at Tech Barcelona's Pier07, the largest tech hub in Southern Europe. Our mission is to transform healthcare from reactive treatment of manifest disease (Sick Care) to proactive, preventive health management (Health Care).

We are developing the EasyMed Foundation Model: a proprietary generative AI architecture that predicts the onset of over 1,000 conditions simultaneously, up to 20 years into the future, using only existing Electronic Health Records (EHRs).

This is the first Foundation Model of this nature and magnitude within the EU, a milestone carrying critical consequences for European digital sovereignty. Our system achieves AUC-ROC scores of 0.85-0.95 on internal validation and 0.7-0.8 on external real-world data. We operate in Digital 5P Medicine (predictive, preventive, personalized, participatory, precision), delivering a B2B/B2G SaaS solution targeting healthcare payors (insurers, public health systems) and pharmaceutical companies (clinical trial recruitment).

EasyMed has been selected for TEF-Health (dual selection in both Portuguese and EU networks), the BSC AI Factory at the Barcelona Supercomputing Center, and the HIPSS Early Access programme for health innovation procurement, validating our technical approach and accelerating our path to market.

Organization name:
EASYMEDAI MEDICAL DATA S.L.

Country: Spain

Type of company: Startup

Year of Foundation: 2025

TRL Level: 6

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Equity

Investment Required: €500K

Product / Solution

The EasyMed Foundation Model is a proprietary generative transformer architecture that learns from historical medical data to predict health trajectories. It predicts the onset of over 1,000 conditions simultaneously with AUC-ROC of 0.85-0.95, up to 20 years into the future. Unlike existing narrow AI systems limited to single diseases and short time windows, our model uses only existing Electronic Health Records (EHRs), eliminating additional data acquisition costs and removing significant barriers to clinical adoption. The architecture handles irregular, incomplete, multi-modal clinical time-series and integrates causal mechanisms to distinguish correlation from causation, ensuring clinical validity and regulatory compliance.

EasyMed is a B2B/B2G SaaS solution with two primary customer segments: (1) Healthcare payors (private insurers, public health systems) who use the model for individual-level risk stratification, enabling targeted prevention that reduces costs; and (2) Pharmaceutical companies who use our Pharma Patient Search Engine for optimized clinical trial recruitment, addressing the current 90%+ trial failure rate. The solution enables a paradigm shift from reactive medicine (treating manifest disease) to high-precision preventive medicine, aligning with the EU Commission's Apply AI Strategy targeting AI-powered healthcare screening.

CONTACT

Iacopo Ciampa, Founder & CEO

E-mail: iacopo.ciampa@easymed.ai

Website: <https://easymed.ai/>



Company Description

Ergobyte Informatics S.A. is a software development company, based in Thessaloniki, Greece, specializing in providing integrated IT solutions for the healthcare sector.

As a digital health SME that builds expert systems and cloud, integrated software, Ergobyte's goal is to transfer information technology from research to market, giving life to innovation through the development and commercialization of cutting-edge software products.

The past ten years, Ergobyte has intensified its efforts to expand to foreign markets. At the same time, the company participates in European research projects, focusing on IT, artificial intelligence and healthcare.

Organization name:
Ergobyte Informatics S.A.

Country: Greece

Type of company: Innovative SME

Year of Foundation: 2010

TRL Level: 6

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Funding

Investment Required: €600K-€1M

Product / Solution

Our company has developed a fully functional, specialized tool for drug adverse reaction prevention, with the aim of improving medical safety and quality of pharmacotherapy. The proposed RxReasoner drug interaction decision support system consists of a technologically mature, tested and interoperable solution that sits between prescribers and order entry systems. The accuracy of its results are guaranteed by a curated knowledge base that comprises 3.300 active pharmaceutical ingredients and their marketing authorization documents.

Our solution concerns the development and integration of a clinical decision support tool (Clinical Decision Support Tool - CDST), which:

- Identifies potential pharmacological interactions and contraindications for co-administration of drugs (Drug to Drug Interaction Cross-Check).
- Identifies potential pharmacological interactions and contraindications for administering drugs with specific diseases (Drug to Disease Interaction Cross-Check), which is a unique tool worldwide.
- Presents to the physician detailed written explanations about all identified risks, with explainable trace to the source material.

As a B2B solution, RxReasoner is designed to be seamlessly integrated as an add-on module into existing electronic prescription systems and, also, third-party software of hospitals, clinics, and pharmacy chains. RxReasoner supports language and culture adaptations for any market.

CONTACT

Maria Zande, Health Informatics Expert

E-mail: mzande@ergobyte.gr

Website: <https://www.ergobyte.gr>



Company Description

Idea Accelerator sp. z o.o. is a Poland-based digital health company in active strategic pivot. HiMommy has reached 2M lifetime downloads and 70K MAU across 12 languages over 7 years. In 2026, we are repositioning toward the first AI-powered digital therapy for postpartum depression prevention.

The pivot is based on three clinical mechanisms already deployed at scale: (1) AI baby-voice daily conversation linked to reduced PPD risk (Rollè 2020, 10/11 studies); (2) HiDaddy app addressing dyadic coping as a key protective factor; and (3) passive AI risk detection via mood and wearable signals identifying PPD risk 2–4 weeks pre-symptoms (Translational Psychiatry 2024, AUC ~0.93).

Regulatory pathway targets EU MDR Class IIa (2028) and DiGA listing in Germany for secondary prevention of PPD (ICD-10 F32 / F33 / F41). As of 2026, no perinatal mental-health DiGA exists in the BfArM directory, despite DigiG 2024 expanding eligibility to pregnant women's health. We aim to be first-to-market.

We operate at the intersection of HealthTech, FemTech, and Digital Therapeutics. Our 2-year longitudinal dataset and 12-language footprint create a defensible moat. We are currently raising a \$10M Series A to fund DiGA, US FDA 510(k), and reimbursement scale.

Organization name:

Idea Accelerator sp. z o.o.

Country:

Poland

Type of company:

Startup

Year of Foundation:

2017

TRL Level:

5

5-Year Revenue Projection after Market Launch:

€5M–€30M

Funding Instrument:

Bootstrapped

Investment Required:

\$10M Series A (in flight)

Product / Solution

HiMommy is an AI-powered perinatal app currently used by 70,000 active mothers across 12 languages, with 2 million lifetime downloads. The product spans the user journey from preconception through the first three years of parenthood, with a particular focus on the pregnancy and early postpartum window — the period of highest maternal mental-health risk and lowest available clinical support. The strategic pivot currently underway repositions HiMommy from a consumer-wellness product to a clinically-positioned digital therapy for postpartum depression prevention. The same daily product, the same dataset — re-framed for clinical evidence generation, regulatory certification, and reimbursement.

Our core differentiator is a daily AI conversation delivered in the voice of the user's baby, beginning at pregnancy week 6 and continuing through toddlerhood. This builds prenatal bonding, the mechanism that the Rollè 2020 systematic review found correlated with reduced PPD risk in 10 of 11 underlying studies. Paired with HiDaddy — our companion app for fathers and partners — the platform delivers a family-system intervention, addressing dyadic coping which the perinatal-couples literature identifies as the single largest protective factor against postpartum depression.

In parallel, we are building a clinical layer: a passive AI risk-detection model on mood and wearable signals that flags rising PPD risk 2–4 weeks before clinical symptoms. This is the foundation for our planned EU MDR Class IIa medical device, targeting DiGA listing in Germany (2028) for secondary prevention of postpartum depression in women with prior diagnosed F32 / F33 / F41 risk indications.

Strategic direction is multi-rail: consumer subscription as the top-of-funnel that already exists, reimbursed digital therapy via DiGA (Germany 2028) and PECAN (France 2029), brand partnerships in perinatal commerce, and US insurance / employer benefits post-FDA 510(k) (target 2030). Our 2-million-download consumer base provides both the longitudinal dataset and the multi-language distribution that no clinically positioned competitor can replicate from a standing start.

Our goal is to be the first AI-powered perinatal digital therapeutic on the EU reimbursement directory — and to make daily preventive support for maternal mental health as routine and accessible as pregnancy tracking is today.

CONTACT

Roman Barzyczak, CEO

E-mail: roman.barzyczak@himommy.com

Website: <https://himommy.app>



Company Description

InSyBio is an AI-driven biotechnology company specializing in biomarker discovery and predictive analytics through its SaaS platform, InSyBio Suite, which delivers end-to-end bioinformatics solutions that empower R&D teams in pharma, clinical research, and nutrition to accelerate discovery, reduce costs, and improve precision.

Complementing this, another platform, InSyBio Diagnostics, translates predictive models into clinically actionable tools in order to solve issues such as chronic pain and cardiovascular diseases. Lately, InSyBio has expanded in the Bioengineering field, applying its machine learning solutions for scaffold design and experimental design optimization.

The company's technologies aim to reduce biomarker discovery time and cost by over 80%, improve predictive accuracy by more than 10%, and support clinically relevant, reproducible, and scalable workflows.

InSyBio's broader ambition is to transition from a seed-stage innovator into a scalable, revenue-generating biomedical AI company through commercialization, strategic partnerships, and regulatory advancement.

Organization name: InSyBio

Country: Greece

Type of company: Startup

Year of Foundation: 2013

TRL Level: 5

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Grant / Equity

Investment Required: €2M

Product / Solution

InSyBio is developing an integrated portfolio of digital health solutions, primarily as B2B SaaS, with some clinician- and patient-facing diagnostic applications.

The flagship InSyBio Suite is an installation-free cloud SaaS platform for biomarker discovery and predictive analytics that integrates multi-omics, clinical, and imaging data into reproducible workflows. InSyBio Diagnostics extends these capabilities into clinically actionable tools, including chronic pain treatment support and cardiovascular prediction tools for physicians and patients.

InSyBio is also proposing a novel Bioengineering Platform that optimizes scaffold design and bioreactor experimental setups for regenerative medicine and tissue engineering. Together, these platforms form a unified precision health ecosystem that supports researchers, pharma and biotech companies, clinicians, hospitals, and bioengineering labs. The model described in the proposal is mainly B2B, based on SaaS subscriptions, licensing, per-test fees, and strategic partnerships.

CONTACT

Harry Zaverdas, Biomedical Data Analyst

E-mail: h.zaverdas@insybio.co.uk

Website: <https://insybio.com/>



Company Description

ITERA NeuroRehab is an Italian digital health startup improving access to neurorehabilitation for people with Parkinson's disease. In Italy, more than 300,000 people live with Parkinson's, yet most struggle to continue physiotherapy consistently due to cost, distance, and limited availability of specialized professionals.

ITERA bridges the gap between clinic and home through a digital platform that connects patients with trained physiotherapists and provides personalized exercise programs based on evidence-based protocols. Patients follow guided sessions at home, receive regular follow-ups, and track their progress over time.

Our approach reflects the principles of Digital 5P Medicine: preventive (supporting early and continuous intervention), personalized and precision-based (tailored rehabilitation plans), participatory (active patient involvement), and predictive (monitoring trends and outcomes).

The business model is subscription-based (€120/month), available directly to patients and through partner clinics. Revenue is shared with physiotherapists. ITERA has a completed MVP and is currently piloting with early users. A 50-patient clinical study is planned for 2026, alongside the regulatory pathway (MDR Class I, progressing to IIa). The current Technology Readiness Level is TRL 5, moving toward TRL 6.

Organization name: Itera rehab srl

Country: Italy

Type of company: Startup

Year of Foundation: 2025

TRL Level: 5

5-Year Revenue Projection after Market Launch: €1M

Funding Instrument: Equity

Investment Required: €260K

Product / Solution

ITERA Rehab is a digital neuro-rehabilitation platform (web/mobile) designed to close the "rehabilitation gap" for people with Parkinson's disease and other chronic neurological conditions by enabling daily, evidence-based exercise at home with professional supervision.

The solution is being developed as Software as a Medical Device (SaMD): the patient app guides exercises and collects self-reported data, while computer-vision modules use a smartphone/tablet camera to quantify movement and extract objective digital biomarkers (e.g., gait speed, postural stability, step symmetry).

A clinician dashboard lets neuro-physiotherapists prescribe personalized protocols, monitor progress and trends, and manage alerts for missed sessions or symptom worsening.

An AI decision-support layer analyzes the patient's baseline evaluation and ongoing performance to recommend the most appropriate protocol (type, intensity, progression) to the therapist, who remains in control of the final prescription and any adjustments.

Business model: hybrid B2C (direct to patients/caregivers) and B2B2C (clinics/physio centers offering ITERA as an extension of care at home).

CONTACT

Andrea Slaviero, CEO

E-mail: andrea.slaviero@iterarehab.com

Website: <https://www.iterarehab.com/>



Company Description

Luperca Medica is a Spanish Deep Tech company legally established on August 28, 2025, in Valladolid. Its primary activity focuses on using Digital Twins (GD) applied to healthcare to realize a personalized, predictive, and safe medical paradigm, overcoming traditional "trial and error" methods based on population averages.

The company's core innovation is an integrated platform providing a system-level, multimodal approach to simulate a full patient's systemic pharmacological response. This is achieved through a hybrid technology that combines Explainable Artificial Intelligence (XAI) with Mechanistic Models (Quantitative Systems Pharmacology - QSP) to ensure biological validity and clinical trust.

Luperca Medica operates across three strategic axes:

1. Personalized Medicine: Creating dynamic patient replicas to simulate individual drug responses, significantly reducing adverse events and hospital readmissions.
2. Pharma R&D: Generating virtual cohorts for in silico clinical trials, which accelerates drug development while reducing costs and ethical risks.
3. Hospital Efficiency: Utilizing Digital Twins of hospital processes to optimize resource management and patient flow.

Operating on a B2B SaaS and consultancy model, the company aims to reduce avoidable healthcare costs by 10%. Supported by regional innovation ecosystems like Wolaria, Abioinnova and SIVI, Luperca Medica is positioned for international expansion within the high-growth European health innovation landscape.

Organization name: Luperca Medica

Country: Spain

Type of company: Startup

Year of Foundation: 2025

TRL Level: 4

5-Year Revenue Projection after Market Launch: €500K-€1M

Funding Instrument: Equity

Investment Required: €300K

Product / Solution

Luperca Médica is developing an integrated platform based on Health Digital Twins (GD)—dynamic virtual replicas of patients. Our solution transforms the traditional "trial and error" medical paradigm into P5 Medicine (Predictive, Preventive, Personalized, Participatory, and Precision) by simulating clinical outcomes before physical intervention.

The product's core innovation is a multimodal, systemic approach that simulates a patient's full systemic pharmacological response. Unlike organ-centric competitors, we utilize a hybrid technology combining Explainable AI (XAI) with Mechanistic Models (Quantitative Systems Pharmacology - QSP). This ensures biological validity and clinical trust by resolving the AI "black box" problem, making predictions transparent for physicians.

Business Model:

- B2B (Current Focus): We operate as a SaaS for hospitals and clinics to optimize treatments and resource management. Additionally, we provide Pharma/CROs with virtual cohorts for in silico clinical trials, significantly reducing R&D costs, ethical risks, and time-to-market.
- B2C (Future Phase): Starting in Year 3, we plan to launch a subscription-based model for individual patients, allowing them to access personalized pharmacogenetic evaluations for proactive health management.

CONTACT

Eva Ferrero, Co-Founder

E-mail: eva.ferrero@lupercamedica.tech

Website: <https://lupercamedica.tech>



Company Description

Medsense is a digital health technology company developing AI-powered tools that transform medical data into actionable health insights for patients and healthcare providers. The platform connects diagnostic data, clinical expertise, and preventive care to support a shift toward proactive and personalized medicine.

Healthcare systems generate large volumes of diagnostic data, yet results are often difficult for patients to interpret and rarely translate into clear next steps. Clinicians also face fragmented information and increasing administrative workload. Medsense addresses this gap by converting diagnostic data into structured insights and contextual information. For individuals, the platform builds personalized health profiles, explains laboratory results, highlights potential risks, and supports preventive monitoring.

For healthcare professionals and hospitals, Medsense provides AI-assisted tools that summarize patient data and support more efficient review of diagnostic information.

Importantly, Medsense functions as a clinical decision-support system. The AI does not make autonomous medical decisions or diagnoses, but assists healthcare professionals by organizing data and identifying patterns.

Organization name:

Medsense Innovations Bulgaria EOOD

Country: Bulgaria

Type of company: Spinoff

Year of Foundation: 2025

TRL Level: 5

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Grant

Investment Required: NA

Product / Solution

AI-powered digital health platform designed to create a structured and efficient communication environment between patients and healthcare professionals. The platform analyzes diagnostic and laboratory data, builds personalized health profiles, and translates complex medical information into clear, curated insights that support informed discussions between patients and doctors.

Unlike standalone health apps, Medsense operates with a doctor-in-the-loop model, ensuring that medical interpretation and decision-making remain under professional supervision. The platform helps patients better understand their health data while enabling physicians to review results faster, access structured summaries, and provide more targeted guidance. This approach reduces time spent on routine explanation and improves the quality and efficiency of patient-doctor interactions.

Medsense follows a B2B and a B2B2C, supporting patients, doctors, laboratories, and healthcare providers with AI-assisted diagnostic interpretation and patient communication tools. By combining automated analysis with curated medical knowledge and clinical oversight, Medsense aims to enhance preventive care, improve health literacy, and streamline clinical workflows.

CONTACT

Maria Hari, Sales and Business Development

E-mail: maria.hari@medsense.me

Website: <https://medsense.me>



Company Description

MYCancer, Lda. is a Portugal-based MedTech startup in functional precision oncology developing the MYLeukaemia Therapy Guidance Chipset, a 72-hour Bone Marrow-on-a-Chip solution for blood cancers. Our mission is to help clinicians know what works for each patient faster by adding functional therapy-response evidence to standard diagnostics. The company's first focus is Acute Myeloid Leukaemia (AML), with future expansion to other haematological malignancies and pharma-supported applications.

Our technology recreates biomimetic human bone-marrow avatars, loads them with patient-derived blood cancer cells, tests clinically relevant regimens, and returns a ranked, tumour-board-ready response report within 72 hours. MYCancer is currently at TRL4, with lab validation already achieved and the next step being prospective clinical pilots. The initial business model is B2B: a centralized lab service for tertiary hospitals, cancer centres and reference laboratories, later complemented by pharma studies and GDPR-compliant data assets.

The company combines deep scientific expertise, IVD/regulatory know-how and healthcare commercialization experience. MYCancer's roadmap is IVDR-aligned, supported by a provisional patent filing, early hospital interest and European recognition including EIT Jumpstarter 2025 Award and EP PerMed Venture Creator finals. MYCancer is building toward CE-IVD market entry as a clinically relevant, workflow-compatible precision oncology platform for Europe.

Organization name: MYCANCER

Country: Portugal

Type of company: Startup / Spinoff

Year of Foundation: 2025

TRL Level: 4

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Grant

Investment Required: NA

Product / Solution

MYCancer is developing the MYLeukaemia Therapy Guidance Chipset, a B2B precision-health solution for blood cancers. The platform recreates human bone-marrow avatars on-chip, loads each patient's live cancer cells, and tests relevant therapies to generate an evidence-ranked, tumour-board-ready report in 72 hours.

We are initially focused on Acute Myeloid Leukaemia (AML), where therapy selection is still often made without directly testing how the individual patient's cells respond. By combining a marrow-mimetic organ-on-chip microenvironment with ex vivo drug-response profiling, MYCancer aims to reduce trial-and-error and support more personalized, clinically relevant treatment selection.

This is not a direct-to-consumer product. Our first customers are hospitals, cancer centres and healthcare providers seeking functional testing that complements standard diagnostics with actionable biological response data. The service is designed to fit real clinical workflows, using a small additional sample collected during routine blood or bone marrow procedures and processed in a central lab. Our second B2B segment is pharmaceutical and biotech companies using the platform for drug validation, translational studies and patient stratification. Over time, we will also build a proprietary, AI-ready response database to support future decision-support tools and R&D partnerships.

MYCancer is currently at TRL4 and advancing toward pilot implementation in regulated clinical settings.

CONTACT

Hugo Caires, Founder & CEO

E-mail: hugo.caires@live.com.pt

Website: <https://www.mycancer.eu/>

NeuReveaL

Company Description

NeuReveaL is a young spin-off of the Sano Centre for Computational Personalised Medicine (Krakow, Poland), and it is driven by the ambition of improving healthcare through earlier detection and prevention of neurological diseases.

It provides cutting-edge technology that transform brain signal data into clinically actionable insights, enabling faster and more accessible diagnostic support. The company envisions a future in which everyone has access to early diagnosis, enabling timely interventions that improve patient outcomes and quality of life.

Our first product addresses the urgent need for earlier identification of cognitive impairment and dementia. We have developed a tool that uses electroencephalography (EEG) data to detect early biomarkers associated with neurodegenerative decline.

By combining advanced AI algorithm with cost-effective EEG hardware, our solution enables scalable and automated screening that can support clinicians in identifying patients at risk at an earlier stage.

This has the potential to revolutionise the fight against dementia by accelerating diagnosis through cost-effective hardware and automated analysis.

Organization name: NeuReveal

Country: Poland

Type of company: Spinoff

Year of Foundation: 2026

TRL Level: 5

5-Year Revenue Projection after Market Launch: >€250K-€500K

Funding Instrument: Equity

Investment Required: €300K

Product / Solution

NeuReveaL is developing NEED (Neuromonitoring EEG for Early Detection of Dementia), a digital screening tool designed to enable earlier identification of cognitive impairment. The solution combines a novel passive visual stimulation protocol with a proprietary machine learning algorithm that analyses EEG signals to detect neural patterns associated with early neurodegenerative changes.

NEED is designed to work with low-density, cost-effective EEG devices, enabling scalable and accessible brain monitoring. Our solution is designed to collect reliable EEG signals, capable of extracting meaningful biomarkers even from noisy signals typically produced by portable devices.

It provides an interpretable risk assessment, and quantifies uncertainty to support clinicians in their diagnostic decision-making process, ensuring transparency and trust in AI-assisted analysis.

The tool can be widely adopted and deployed even in underserved areas (e.g., rural settlements or low-income countries), can be used by clinical staff who are, or not, specialised in dementia or be expert in EEG, providing an efficient tool for large-scale screening.

NEED is offered as a B2B solution via a license-based service to healthcare providers and diagnostic centres.

In a preliminary real-world pilot study conducted in a day-care facility for older adults, the system achieved 88% accuracy in identifying early signs of cognitive impairment in a cohort of 24 participants.

CONTACT

Rosmary Blanco, Founder & CTO/CSO

E-mail: r.blanco@sanoscience.org

Website: NA



Company Description

Niverbec is an innovative Italian startup founded by a multidisciplinary team that brings together expertise from healthcare, technology, design, operations and communication. United by a shared vision, the team works at the intersection of human needs and digital transformation, with the goal of developing solutions that make assistance more effective, accessible and person-centred.

Niverbec approaches innovation with a strong sense of responsibility: listening carefully to real-world stakeholders, translating complex challenges into simple experiences, and designing services that can be adopted in everyday life without friction.

The company's culture is built on collaboration, agility and trust. Different professional backgrounds are not treated as separate domains, but as complementary perspectives that strengthen decision-making and accelerate execution.

From early research and validation to product development and partnerships, Niverbec focuses on creating measurable impact and long-term value, supporting people and communities in moments when reliability and clarity matter most. With a mission rooted in improving quality of life, Niverbec invests in scalable innovation that aligns with modern standards of safety, privacy and inclusion, aiming to contribute to a more resilient and responsive care ecosystem.

Organization name: Niverbec

Country: Italy

Type of company: Startup

Year of Foundation: 2022

TRL Level: 6

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Equity

Investment Required: NA

Product / Solution

Niver is a digital emergency-care service developed by Niverbec that enables authorised first responders to access, within seconds, a patient's essential, doctor-certified emergency information.

The core element is an Emergency Sheet containing critical data such as allergies, ongoing therapies, relevant conditions, emergency contacts and advance directives, designed to be immediately usable in emergency scenarios where the patient may be unconscious, confused, or unable to communicate due to language barriers. Access is triggered through a personal digital key embedded in an everyday object, thanks to a NFC-R card or wearable. No health data is stored on the device: it acts only as a secure key to retrieve information from a certified cloud infrastructure built with privacy-by-design, encryption, strong authentication and full access traceability.

Niver is commercialised through a hybrid B2B and B2C model: Niver partners with organisations that benefit from improved emergency readiness and risk reduction, such as associations, insurers, corporate welfare programmes, mobility and transport operators, and emergency ecosystem stakeholders, enabling large-scale distribution and faster adoption.

The solution is designed to be simple to adopt, scalable, and complementary to public digital health infrastructures, improving response quality by reducing uncertainty when every second counts.

CONTACT

Filippo Ferrari, CTO

E-mail: f.ferrari@niverbec.com; info@niverbec.com

Website: <https://www.niverbec.com>



Company Description

OneCareAI is a Barcelona-based digital health startup and spin-off of the Barcelona Supercomputing Center, founded in April 2025. The company develops artificial intelligence solutions to identify individuals at risk of stroke by analyzing electrocardiogram (ECG) data.

The company was founded by two researchers from the Barcelona Supercomputing Center: Daniele Lezzi (CTO), from the Computer Sciences Department, and Davide Cirillo (CSO), leader of the Machine Learning for Life Sciences group. The CEO, Xavier Guillem, joined during the Mobile World Capital Foundation Collider Program and co-founded the company. The shareholder structure includes both the Barcelona Supercomputing Center and the Mobile World Capital Foundation.

OneCareAI builds on several years of research in artificial intelligence, biomedical data analysis, and digital health technologies developed at BSC. The company's mission is to translate this research into scalable clinical tools that support early detection and prevention of cardiovascular diseases, particularly stroke.

By combining expertise in artificial intelligence, clinical research, and digital health entrepreneurship, OneCareAI aims to develop innovative Software as a Medical Device (SaMD) solutions capable of improving preventive cardiology and enabling more proactive patient care.

Organization name: OneCareAI

Country: Spain

Type of company: Spinoff

Year of Foundation: 2025

TRL Level: 5

5-Year Revenue Projection after Market Launch: €500K-€1M

Funding Instrument: Grant

Investment Required: NA

Product / Solution

OneCareAI is developing an AI-powered Software as a Medical Device (SaMD) platform designed to identify patients at risk of hidden (occult) atrial fibrillation using routine electrocardiograms (ECGs).

Atrial fibrillation is one of the leading causes of stroke, yet many cases remain undetected because AF episodes can be intermittent and asymptomatic. Current diagnostic strategies often rely on prolonged monitoring, which can be costly and inefficient when applied to large populations.

Our solution analyzes ECG patterns and extracts predictive features associated with the biological mechanisms linked to cardioembolic stroke. By estimating an individual's propensity to develop atrial fibrillation, the platform helps clinicians identify patients who may benefit from preventive monitoring such as Holter devices or wearable ECG technologies.

The system includes a secure digital platform with a cloud-based infrastructure, a clinical dashboard for physicians, and integration with ECG data from hospital devices and wearable technologies.

OneCareAI operates under a B2B SaaS model, offering subscription-based access to hospitals, cardiology services, insurers, and ECG service providers. By enabling earlier identification of high-risk patients and guiding targeted monitoring strategies, the platform aims to improve stroke prevention, reduce healthcare costs, and support data-driven cardiovascular care.

CONTACT

Daniele Lezzi, CTO & Co-Founder

E-mail: daniele.lezzi@onecareai.com

Website: <https://www.onecareai.com>



Company Description

Celentis is a Deep Tech and MedTech spin-off originating from the Universitat Politècnica de València (UPV) and the Universitat de València (UV) in Spain.

We specialize in the research, development, and manufacturing of advanced chemical sensors for precision diagnostics and biomedical research. Our mission is to bridge the gap between academic innovation and clinical application by providing highly reliable, real-time molecular recognition tools.

Born from the prestigious Interuniversity Research Institute for Molecular Recognition and Technological Development (IDM), Celentis leverages cutting-edge synthetic chemistry to create proprietary probes.

We are currently bootstrapping our growth, supported by strategic non-dilutive public funding for R&D. Our agile structure allows us to develop highly specialized diagnostic kits, effectively addressing critical bottlenecks in cellular monitoring and disease detection.

Organization name: OPTICALSENS, S.L.

Country: Spain

Type of company: Startup / Spinoff

Year of Foundation: 2024

TRL Level: 6

5-Year Revenue Projection after Market Launch: €100K-€250K

Funding Instrument: Grant

Investment Required: NA

Product / Solution

Celentis develops advanced chemical sensing solutions across two primary product lines, targeting both clinical diagnostics and public health safety:

Senoprobes (MedTech): A B2B solution based on our fluorescence sensors technology. We have three advanced sensor kits designed to detect cellular senescence ("zombie cells") in real-time within living tissues. Currently a Research Use Only (RUO) tool for pharma and academia researching aging and cancer, its non-destructive nature allows continuous cell/animal monitoring. This opens the door to a certified In Vitro Diagnostic (IVD) tool, offering clinicians a personalized biomarker to evaluate patient health and the efficacy of oncological or senolytic treatments.

Preventive Bracelets (Public Health/Safety): A B2B/B2G and B2C solution addressing the critical threat of chemical submission. We have developed and commercialized wearable bracelets equipped with proprietary chemical sensors that instantly detect date-rape drugs in beverages. Currently successfully sold to public institutions and City Councils, these scientifically validated bracelets provide a reliable, real-time protection tool in leisure environments.

CONTACT

Isabel Caballos, Head of R&D

E-mail: celentis@celentis.bio

Website: <https://celentis.bio/es/inicio/>



Company Description

Pausetiv is a digital health company developing a data-driven clinical platform dedicated to the assessment, monitoring and personalized management of women's health during perimenopause and menopause. The company addresses a major unmet clinical need: despite affecting over one billion women globally, menopause remains significantly underdiagnosed and undertreated, with long-term implications for cardiovascular, metabolic, cognitive and bone health.

Pausetiv combines a proprietary multidisciplinary clinical protocol with digital tools for symptom tracking, patient stratification and personalized treatment pathway generation. The platform integrates clinical data, patient-reported outcomes and longitudinal monitoring to support clinical decision-making and improve time-to-diagnosis and treatment optimization.

The solution is designed to operate within regulated healthcare environments, supporting telemedicine delivery and building toward future clinical decision support and digital medical device pathways. The company is progressively building a structured health data layer to enable predictive and preventive approaches to chronic disease risk management in midlife women.

Pausetiv operates through a B2B2C model, working with specialist networks, healthcare providers, corporate welfare platforms and insurance partners to scale access to evidence-based menopause care.

The company is currently at MVP stage with early patient adoption, validated clinical workflow.

Organization name: Pausetiv Srl

Country: Italy

Type of company: Startup

Year of Foundation: 2024

TRL Level: 5

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Pre-seed Funding

Investment Required: €750K

Product / Solution

Pausetiv is developing a digital health platform designed to support the clinical assessment, monitoring and personalized management of women's health during perimenopause and menopause, addressing a major unmet clinical need affecting over one billion women globally.

The platform combines a proprietary multidisciplinary clinical protocol with digital tools for symptom tracking, patient stratification and personalized treatment pathway generation. It integrates clinical data, patient-reported outcomes and longitudinal monitoring to support clinical decision-making, reduce time-to-diagnosis and improve treatment optimization.

The solution is designed to operate within regulated healthcare environments, supporting telemedicine delivery and building toward future clinical decision support and digital medical device pathways. Pausetiv is also developing a structured health data layer to enable predictive and preventive approaches to chronic disease risk management in midlife women.

Pausetiv operates through a hybrid B2C and B2B2C model. B2C includes direct access to digital assessment and personalized care pathways. B2B2C includes partnerships with healthcare providers, corporate welfare platforms and insurance partners to scale access to evidence-based menopause care.

CONTACT

Clarice Pinto, Founder & CEO

E-mail: clarice.pinto@pausetiv.com

Website: <https://www.pausetiv.com/>



Psychomeasure

Company Description

Psychomeasure is a healthtech company focused on using computational language analysis to improve mental health assessment and monitoring. We develop products that automate speech analysis and convert patterns in language into data and visual graphs, producing insights that can help identify individuals at risk and support the diagnosis and monitoring of mental health conditions.

Our company's clinical platform uses natural language processing (NLP), machine learning, and graph theory to analyze speech structure and connectedness as cognitive markers, with an initial focus on schizophrenia and other psychiatric conditions. Scalable and language-independent, it supports broader international use.

We emphasize responsible use: automation is limited to translating speech patterns into visual outputs, while clinical interpretation for diagnosis should be done by accredited mental health providers. Psychomeasure use data protection measures such as encryption and restricted access to protect confidentiality.

From a business perspective, our business model is Software-as-a-Service (SaaS) model, initially targeting B2B customers such as mental health clinics and hospitals. We are developing Digital Therapeutics (DTx) powered by computational language biomarkers and to improve mental health care while broadening language coverage as part of growth and internationalization.

Organization name: Psychomeasure

Country: Portugal

Type of company: Startup

Year of Foundation: 2019

TRL Level: 6

5-Year Revenue Projection after Market Launch: >€20M

Funding Instrument: Equity

Investment Required: €500K

Product / Solution

We address a major clinical gap in mental health: many conditions, including schizophrenia, are still assessed through time-consuming, subjective methods, which can delay treatment and make follow-up inconsistent.

Our solution focuses on making assessment and monitoring more objective and scalable by converting brief speech samples into quantitative markers and visual outputs that support clinicians in earlier detection, faster evaluation, and longitudinal monitoring.

The primary market is B2B healthcare, including mental health clinics, hospitals, and providers seeking digital tools to improve diagnostic workflows and patient monitoring. In market-size terms, Psychomeasure operates within the broader global mental health services market, which multiple market reports estimate in the range of roughly USD 410B (2023) to about USD 426.6B (2024), with projections reaching approximately USD 553B–573B by the early 2030s. This positions the company within a large and growing healthcare segment where the need for more efficient, objective, and scalable assessment is increasing.

CONTACT

Eduardo Sampaio, CEO

E-mail: info@psychomeasure.com

Website: <https://psychomeasure.com/>



Company Description

Re4Life Healthcare Technologies: Founded by Dr. Eng. Petko Stoev, the company aims to revolutionize rehabilitation and improve the lives of people with disabilities through robotics.

Innovative Solutions: Developing two products – a remote rehabilitation exoskeleton and an autonomous robot that attaches to wheelchairs, allowing users to stand and move independently.

Funding & Recognition: The project has won several grants and individual investor funding, including “Science with a Future III” from the America for Bulgaria Foundation and the “Entrepreneur in Science” award from the Karol Knowledge Foundation.

The Team: The company has a diverse team of professionals working across the globe – Bulgaria, Switzerland, Georgia, Greece, Germany and others. Apart from our medical experts, we work closely with hospital representatives, as well as people with disabilities in order to achieve excellence in our products.

Organization name: Re4Life

Country: Bulgaria

Type of company: Startup

Year of Foundation: 2023

TRL Level: 5

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Equity

Investment Required: €1.2M

Product / Solution

Telemedicine Exoskeleton: A modular robotic upper-limb device for stroke and trauma recovery. Unlike rigid competitors, our hardware is natively ambidextrous (compatible with both arms) and integrated with a cloud-based telemedicine platform. This allows clinicians to prescribe and monitor intensive therapy remotely, ensuring continuity of care outside the hospital.

4FREEDOM: We propose a new category of assistive robotics: a mobile humanoid-like transforming robot with two operating modes designed specifically for wheelchair users:

Mode 1 – Transfer & Stand Mobility. The robot mechanically couples to a wheelchair, safely transfers the user from the wheelchair into the robot, lifts them into an upright standing position, and then transports them while standing in indoor environments. Stability on slopes and uneven terrain is achieved through an adaptive rear wheel mounted on a linear actuator, which dynamically adjusts the support and centre of mass.

Mode 2 – Home Service. The same robot operates as an autonomous mobile assistant in the home, with an integrated robotic arm and camera. Through a smartphone application, the user can command missions such as “go to the kitchen, pick up a glass of water from a surface and bring it to me”.

Business Model:

- B2G – Government procurement and welfare grants,
- B2B – Direct sales to rehabilitation centers and private clinics, starting in Bulgaria.
- MaaS – Mobility-as-a-Service monthly rental model to lower upfront costs.

CONTACT

Petko Stoev, CEO

E-mail: petko_ivanov_stoev@abv.bg

Website: <https://re4life.eu/>

SaviKids

Company Description

SaviKids is an AI-powered digital platform designed to support children with diverse learning needs by transforming traditional educational content into personalized and accessible learning experiences.

Many children struggle with school not because they lack ability, but because lessons are presented in a format that does not match how they learn. This is particularly true for children with attention difficulties, anxiety, dyslexia, autism spectrum conditions, or other learning differences.

SaviKids addresses this challenge by using artificial intelligence to transform educational material into adaptive learning formats adapted to each child's cognitive profile and interests. A parent or child can simply take a photo of a lesson, and the platform converts it into simplified explanations, stories, visual elements, or interactive exercises that match the child's attention span, reading level, and preferred learning style.

In addition to academic support, SaviKids integrates emotional regulation tools such as breathing exercises and guided calm moments to help children manage stress and maintain focus during learning. By combining personalized AI-driven learning with cognitive and emotional support, SavvyKids aims to reduce learning frustration, increase engagement, and support healthier developmental outcomes for children facing educational challenges.

Organization name: SaviKids

Country: Bulgaria

Type of company: Startup

Year of Foundation: NA

TRL Level: 5

5-Year Revenue Projection after Market Launch: €500K-€1M

Funding Instrument: Grant

Investment Required: NA

Product / Solution

SaviKids is a digital platform for children who need learning content presented in a more adapted and supportive way. The app helps families turn school material into simpler, more engaging formats that fit the child's level, pace and interests. A parent can upload or photograph a lesson, and SaviKids transforms it into clearer explanations, stories, visual supports and short activities that are easier for the child to follow.

The platform is built for children with different learning profiles, including those with attention difficulties, anxiety, dyslexia or autism, as well as children who simply do not respond well to standard teaching formats. SaviKids also includes calming tools such as breathing and focus activities to support emotional balance during learning.

The solution is mainly B2C in its first phase, aimed at parents and families. In parallel, it is also designed to grow into a B2B offer for schools, therapists, psychologists, speech therapists and educational centres looking for more adapted support tools for children.

CONTACT

Bojidara Doseva, Co-Founder

E-mail: dara.doseva@gmail.com

Website: <https://www.savikids.com/en>



Company Description

What happens when a clinical psychiatrist (PhD in biotech) and an AI engineer (successful exit, F1-grade engineering) decide to tackle depression? WakeZ.

We built the hard parts first: a polysomnography-aligned sleep-staging stack, an Apple Watch data pipeline, and 5 clinical studies showing REM-sleep biomarkers track depressive severity and that precisely timed wrist haptics can modulate REM during home sleep as a non-drug treatment for depression.

WakeZ delivers depression “detect + act” from the wrist, at night, using Apple Watch. Detect: passive monitoring builds an individual baseline and flags persistent risk trends earlier than sporadic check-ins. Act: closed-loop micro-haptics delivered during detected REM aim to reduce next-day symptom burden, while Smart Alarm helps users wake up refreshed around a chosen time.

We are a software medical device manufacturer under EUDAMED and ANMDM, operating under an audited QMS.

Depression affects ~280M people globally, while mental ill-health costs Europe >€600B/year. With long delays in access to care, WakeZ offers a passive, at-home, pill-free intervention designed to support earlier detection and improve quality of life.

Organization name: WakeZ

Country: Romania

Type of company: Startup

Year of Foundation: 2022

TRL Level: 6

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Equity

Investment Required: €1.5M

Product / Solution

WakeZ is a wearable-first sleep platform that combines continuous monitoring with closed-loop intervention to support depression prevention and symptom reduction. The product runs on Apple Watch and delivers two core capabilities in one user journey.

1. Detect: WakeZ turns nightly sleep signals into an individualized baseline and a simple “Depression Risk Trend” that updates over days/weeks (stable / shifting / concerning). The goal is earlier detection of persistent deviations (especially in REM dynamics) than sporadic self-reports, plus clearer, objective monitoring for relapse prevention. When a sustained pattern emerges, WakeZ can generate a clinician-ready summary for review.

2. Act: WakeZ doesn’t just measure sleep, it acts upon it. During REM, WakeZ can deliver brief, gentle haptics intended to dampen excessive REM without fully waking the user, improving symptoms of depression - a clinically validated effect. For healthy individuals, at a user-selected time, Smart Alarm uses personalized micro-haptics to steer you toward light sleep so you wake up feeling better.

Business model: primarily B2B2C. Employers, clinics, and digital health partners offer WakeZ as a benefit or care pathway; end users use the app daily; clinicians/care teams access an optional dashboard for oversight. Secondarily B2B: WakeZ can be licensed as remote sleep/mental-health monitoring and digital endpoints for clinical trials and research programs.

CONTACT

Zaki Milhem, Scientific Director

E-mail: zaki@wakez.ai

Website: <https://wakez.ai/>



Company Description

Tendertec is a women-led SME transforming care from reactive to proactive. We address workforce shortages through Hestia, a privacy-first ambient digital assistant that converts passive thermal signals into real-time safety and early-risk insights.

Built and validated in homes and care facilities, Hestia detects behavioural changes, hidden falls, and early signs of deterioration before escalation leads to hospitalisation or crisis. Using passive thermal sensing and behaviour modelling, it learns routines without recording identifiable data or requiring user input, creating a dignified, zero-intrusion safety net.

Carers receive real-time alerts that support prevention and free time for human care. By enabling earlier intervention, Hestia reduces avoidable admissions, improves outcomes, and alleviates workforce pressure.

Founded from lived experience as remote carers for ageing parents, Tendertec combines frontline understanding with a circular hardware design that makes sensors durable, repairable, and redeployable, reducing cost and e-waste. Hestia has been deployed across multiple care environments. A recent 12-month pilot identified 100+ hidden falls and 400 near-falls, delivering up to 38x ROI in high-risk cohorts and freeing up to 20% staff capacity.

Organization name:

Tendertec Hellas IKE

Country: Greece

Type of company: Innovative SME

Year of Foundation: 2020

TRL Level: 6

5-Year Revenue Projection after Market Launch: €100K-€250K

Funding Instrument: Equity

Investment Required: €1.5M

Product / Solution

Hestia is our privacy-first ambient sensing and behavioural intelligence platform designed to shift long-term care from reactive to proactive, personalised prevention.

Using low-resolution long-wave infrared sensing combined with a proprietary edge-to-cloud AI pipeline trained on real-world datasets, Hestia detects pose, movement patterns, and subtle behavioural changes.

Hestia is a continuous behavioural intelligence layer that adapts across care pathways as needs evolve. It detects hidden falls and near-falls, monitors night-time risk, and identifies early signs of functional or health deterioration, enabling earlier intervention before escalation to injury, hospitalisation, or crisis.

Through KPI-gated pilot we have tested Hestia (including real-time alerts, user interface) to prevent escalation and guide daily care. So far, it has identified over 1,300 falls and 6,300+ near-falls, generating actionable, real-time alerts that support safer, more efficient care delivery.

Hestia is primarily a B2B solution targeting care home providers and supported living operators facing acute workforce shortages and rising acuity. By prioritising high-risk individuals and reducing avoidable incidents, it frees frontline capacity while improving outcomes. A secondary B2C channel supports families seeking preventive, dignified monitoring for loved ones ageing at home.

Our ambition is to establish Hestia as Europe's privacy-preserving behavioural intelligence standard for ageing society.

CONTACT

Maria Konidari, CEO & Co-Founder

E-mail: contact@tendertec.org

Website: <https://tendertec.org/>



Company Description

Thermovision develops technology that brings biological skin monitoring into everyday life. Using thermal imaging and software analysis, our solution detects subtle temperature variations on the skin and transforms them into measurable data over time.

This allows users to monitor physiological changes that may indicate inflammation, abnormal blood flow, or other skin-related conditions before visible structural changes appear.

Our goal is to provide accessible, non-invasive monitoring tools that help individuals track changes between medical visits and support more informed discussions with healthcare professionals.

Organization name: Thermovision

Country: Romania

Type of company: Startup

Year of Foundation: 2022

TRL Level: 5

5-Year Revenue Projection after Market Launch: >€1M

Funding Instrument: Grant

Investment Required: NA

*Primarily funded through parent company capital.

Product / Solution

Thermovision is a skin monitoring solution that uses thermal imaging technology to detect and track subtle temperature variations on the skin over time. These variations can indicate physiological changes such as inflammation, abnormal blood flow, or other early signs that may require medical attention.

Our solution combines a compact thermal camera with a software platform that analyzes thermal patterns and highlights areas that may need monitoring. Instead of relying only on visual inspection, Thermovision provides measurable data that helps users observe changes between medical visits.

The solution is designed as a hybrid model.

For individuals (B2C), it provides an accessible tool for regular skin monitoring and awareness.

For clinics and healthcare professionals (B2B), it offers a supportive diagnostic aid that helps structure observations and improve patient monitoring.

CONTACT

Mariana Botezatu, Project Manager

E-mail: mariana.botezatu@sipstatus.com

Website: <https://thermovisionscan.com/>



Company Description

ThetaBiomarkers, a 2022 spin-off of the Aristotle University of Thessaloniki, delivers advanced metabolomics and bioanalysis supporting health, wellbeing, and sustainable innovation, aligned with the European Union's One Health approach.

Using state-of-the-art LC-MS/MS and GC-MS/MS, we provide high-quality quantitative analysis of a broad range of biomarkers through validated, fit-for-purpose methods and personalized reports with advanced data visualization against own reference ranges.

Our team of seven PhD scientists combines strong academic excellence with industry experience and an extensive network of health and nutrition professionals, enabling reliable biomarker discovery, metabolism tracking, and tailor-made Science-to-Business solutions for research, healthcare, nutrition, and wellness.

Organization name: ThetaBiomarkers

Country: Greece

Type of company: Spinoff

Year of Foundation: 2022

TRL Level: 4

5-Year Revenue Projection after Market Launch: €250K-€500K

Funding Instrument: Grant

Investment Required: NA

Product / Solution

We are developing an affordable (~€70) blood test for Type 2 Diabetes (T2D) risk assessment, patient stratification and monitoring. The test combines 14 metabolic markers into a single, easy-to-interpret risk score that complements existing measures such as HbA1c and fasting glucose.

Our solution goes beyond simple glucose measurement. It helps identify: (i) individuals at high risk or in prediabetic stages, (ii) mid-term blood sugar fluctuations, (iii) early signs of insulin resistance, and (iv) patient response to lifestyle, dietary or pharmaceutical interventions. The output is a clear index score designed to support clinical and practical decision-making. ThetaBiomarkers offers this as a B2B solution for life science companies, diagnostic laboratories, clinicians, nutritionists and healthcare providers seeking a reliable metabolic risk tool. The test can be integrated into preventive health programs, diabetes clinics, corporate wellness schemes and personalized nutrition services.

The analytical method has been fully validated and tested in 360 real-world blood samples. We are now validating further with 700 well-characterized samples (controls, prediabetic and diabetic individuals), supported by clinical and lifestyle data, to further confirm performance and clinical utility. Our AI algorithm combines our unique panel with classic biochemistry, anthropometric and activity data to give a score that is measurable and understandable and tangible for patient and health staff.

CONTACT

Georgios Theodoridis, CEO

E-mail: georgiostheodoridis@thetabiomarkers.com

Website: <https://thetabiomarkers.com/>



Company Description

One billion people need speech therapy. It sits at the intersection of neuroscience and mental health - shaping how we think, feel, and connect. Stuttering alone affects 80 million people worldwide. Yet 90% never get access to care.

For the ones who do, traditional speech therapy often follows a "low-frequency" model (1-2 sessions per week), but progress depends on what happens in between. Patients need to practice daily and most don't. Not because they don't want to. Because there's no support, no structure, no feedback.

The result: low adherence, longer treatments, and clinics unable to serve more patients. More demand, non-billable hours, and no scalable way to deliver care.

UpSpeech is a health-tech startup that closes this gap by making speech therapy continuous. Our AI-powered platform extends the reach of the therapist into the patient's daily life, giving patients a clinical companion at home while giving clinics the tools to serve more patients without adding staff.

Organization name: UpSpeech

Country: Portugal

Type of company: Startup

Year of Foundation: 2025

TRL Level: 5

5-Year Revenue Projection after Market Launch: €5M

Funding Instrument: Grant

Investment Required: NA

Product / Solution

UpSpeech is a B2B2C platform designed to scale the entire speech therapy lifecycle, from evaluation to treatment planning to personalised daily practice. We are currently in MVP stage, running our first pilot with SpeechCare, one of the world's leading stuttering centers. For clinics and therapists, UpSpeech is a clinical force multiplier. Our multimodal AI captures audio, facial cues, and contextual data simultaneously, giving therapists a complete clinical picture of every home practice session, where it matters the most.

What makes UpSpeech distinct is the connected loop: a therapist sets the plan, the patient practices with AI support, and the therapist reviews annotated recordings and adjusts treatment, all within a single platform. Clinics monetise this loop directly, by billing continuous digital care as a formal session.

CONTACT

Rodrigo Figueiredo, Founder & CEO

E-mail: rodrigodsbfigueiredo@gmail.com

Website: <https://upspeech.app/>

PROJECT PARTNERS



Contact Us

Website: <https://medicnest.eu/innomedcatalyst/>

Email: innomedcatalyst@medicnest.eu



**Funded by
the European Union**